Korea Pharma

(주)한국파마 · KOSDAQ · 032300 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩26.5bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+2.1% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+10.2% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026₩3.2bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+47.3% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+528.7% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩1.0bn As of Oct 2, 2026 Source 1
Buyback decided, last 3 months, % of sharesNot available
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of sharesNot available
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of sharesNot available
Buyback decided, last 12 months₩1.0bn As of Oct 2, 2026 Source 1
Buyback decided, last 12 months, % of sharesNot available
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of sharesNot available
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of sharesNot available

Potential dilution

CB/BW/EB issued, last 12 months₩15.0bn As of May 20, 2026 Source 1 ↗
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months1,391,207 shares As of May 20, 2026 Source 1 ↗
Potential new shares, % of sharesNot available
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months1 As of Nov 19, 2026
DART filings, previous 3 months4 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)0 shares As of Nov 19, 2026
Insiders who bought, last 12 months0 As of Nov 19, 2026

Insider transactions (last 12 months)

No insider transactions in the last 12 months.

Annual financials

YearRevenueOperating income
2025₩87.6bn-₩887m
2024₩81.3bn₩6.1bn
2023₩83.2bn₩6.3bn

Filing timeline